OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Consensus Rating of “Hold” by Analysts

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) has been given an average rating of “Hold” by the five analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $6.3333.

OKYO has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a research note on Tuesday, April 21st. Piper Sandler started coverage on shares of OKYO Pharma in a report on Friday, February 20th. They issued an “overweight” rating and a $7.00 price objective for the company.

OKYO Pharma Stock Performance

OKYO opened at $1.72 on Friday. The stock’s 50 day moving average price is $1.61 and its 200 day moving average price is $1.88. OKYO Pharma has a 12 month low of $1.44 and a 12 month high of $3.35.

Institutional Trading of OKYO Pharma

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its stake in shares of OKYO Pharma by 235.0% in the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after acquiring an additional 96,800 shares during the period. XTX Topco Ltd acquired a new position in shares of OKYO Pharma during the fourth quarter valued at approximately $36,000. Finally, Citadel Advisors LLC bought a new stake in OKYO Pharma during the third quarter worth approximately $31,000. 2.97% of the stock is owned by institutional investors and hedge funds.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.